Interaction between pathogenic proteins in neurodegenerative disorders.

Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci (2015) 1.53

Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol (2012) 1.32

Protein-protein interactions: general trends in the relationship between binding affinity and interfacial buried surface area. Protein Sci (2013) 1.20

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease. Acta Neuropathol (2013) 1.15

Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. Alzheimers Res Ther (2014) 1.11

Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm (Vienna) (2014) 0.92

Early Alzheimer's and Parkinson's disease pathology in urban children: Friend versus Foe responses--it is time to face the evidence. Biomed Res Int (2013) 0.90

Splicing factor TRA2B is required for neural progenitor survival. J Comp Neurol (2014) 0.89

Beta-Amyloid Precursor Protein (βAPP) Processing in Alzheimer's Disease (AD) and Age-Related Macular Degeneration (AMD). Mol Neurobiol (2014) 0.87

Elevated protein carbonylation, and misfolding in sciatic nerve from db/db and Sod1(-/-) mice: plausible link between oxidative stress and demyelination. PLoS One (2013) 0.86

Parkinson disease and progressive supranuclear palsy: protein expression in skin. Ann Clin Transl Neurol (2016) 0.82

Treatment of dementia with lewy bodies. Curr Treat Options Neurol (2013) 0.81

Extracellular α-synuclein leads to microtubule destabilization via GSK-3β-dependent Tau phosphorylation in PC12 cells. PLoS One (2014) 0.80

Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PLoS One (2013) 0.79

Pathological α-synuclein impairs adult-born granule cell development and functional integration in the olfactory bulb. Nat Commun (2014) 0.78

Functional genomics approach for identification of molecular processes underlying neurodegenerative disorders in prion diseases. Curr Genomics (2012) 0.77

Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction. Neurobiol Aging (2014) 0.77

Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS One (2015) 0.77

Inhibition of UCH-L1 in oligodendroglial cells results in microtubule stabilization and prevents α-synuclein aggregate formation by activating the autophagic pathway: implications for multiple system atrophy. Front Cell Neurosci (2015) 0.77

Concomitant accumulation of α-synuclein and TDP-43 in a patient with corticobasal degeneration. J Neurol (2014) 0.77

ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease. Mol Neurobiol (2016) 0.75

A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses. Sci Rep (2016) 0.75

Proteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer's hippocampus from normal controls. Aging Cell (2016) 0.75

Solvent microenvironments and copper binding alters the conformation and toxicity of a prion fragment. PLoS One (2013) 0.75

Quantum dots and prion proteins: is this a new challenge for neurodegenerative diseases imaging? Prion (2013) 0.75

Wild type huntingtin toxicity in yeast: Implications for the role of amyloid cross-seeding in polyQ diseases. Prion (2016) 0.75

Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils. Int J Nanomedicine (2013) 0.75

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Alzheimers Res Ther (2017) 0.75

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51

Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03

Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09

A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03

Alzheimer's disease is a synaptic failure. Science (2002) 13.82

Adapting proteostasis for disease intervention. Science (2008) 13.22

Alzheimer's disease. N Engl J Med (2010) 13.13

Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85

Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56

Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 7.73

Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52

Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99

Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87

Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging (1995) 6.86

Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47

Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17

Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07

Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 5.76

The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol (2010) 5.59

The most infectious prion protein particles. Nature (2005) 5.37

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res (2008) 5.29

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature (2011) 5.27

Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem (2009) 5.23

Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88

Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74

In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A (2011) 4.38

Structural classification of toxic amyloid oligomers. J Biol Chem (2008) 4.16

A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15

Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07

Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A (2006) 3.98

Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science (2010) 3.98

Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci (2005) 3.93

TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol (2010) 3.92

The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. J Cell Biol (2007) 3.83

A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature (2006) 3.76

Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76

Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol (2011) 3.69

Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci (2005) 3.69

Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci (2009) 3.68

The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron (2009) 3.68

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61

Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol (2009) 3.55

Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55

α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest (2011) 3.53

Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A (2009) 3.47

Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron (2008) 3.46

Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol (2002) 3.35

Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol (2010) 3.34

Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett (2005) 3.30

Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28

Caspase activation precedes and leads to tangles. Nature (2010) 3.24

Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A (2011) 3.23

Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22

Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci (2007) 3.16

The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12

Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11

Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron (2008) 3.08

Mitochondria: the next (neurode)generation. Neuron (2011) 3.06

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03

Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol (2011) 2.94

Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem (2011) 2.86

Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci (2011) 2.84

Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med (2008) 2.80

Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol (2008) 2.78

Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature (2011) 2.74

Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov (2010) 2.58

Tau reduction prevents Abeta-induced defects in axonal transport. Science (2010) 2.57

Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol (2006) 2.57

Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51

Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci (2010) 2.46

Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci (2006) 2.45

beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40

Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res (2007) 2.38

Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem (2008) 2.34

Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem (2007) 2.32

Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci (2010) 2.29

Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A (2009) 2.27

A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci (2010) 2.22

Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20

Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A (2009) 2.14

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol (2010) 2.13

Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12

The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci (2010) 2.10

Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09

The genetic epidemiology of neurodegenerative disease. J Clin Invest (2005) 2.08

Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A (2009) 2.04

Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol (2009) 2.01

Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging (2007) 1.99

Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord (2008) 1.98

Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem (2011) 1.96

Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun (2011) 1.96

Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95

Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord (2011) 1.62

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol (2008) 1.52

Neuropathological spectrum of synucleinopathies. Mov Disord (2003) 1.35

Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) (2009) 1.27

The pathology of "vascular dementia": a critical update. J Alzheimers Dis (2008) 1.25

Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis (2008) 1.20

Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord (2005) 1.02

Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis (2007) 1.00

Prevalence and pathology of vascular dementia in the oldest-old. J Alzheimers Dis (2010) 0.92

Prevalence and pathology of dementia with Lewy bodies in the oldest old: a comparison with other dementing disorders. Dement Geriatr Cogn Disord (2011) 0.88

Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci (2009) 0.88

Neuropathology and general autopsy findings in nondemented aged subjects. Clin Neuropathol (2012) 0.88

Four-repeat tauopathy clinically presenting as posterior cortical atrophy: atypical corticobasal degeneration? Acta Neuropathol (2010) 0.87

Neuropathological approaches to cerebral aging and neuroplasticity. Dialogues Clin Neurosci (2013) 0.87

Is there pure vascular dementia in old age? J Neurol Sci (2010) 0.86

Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker? J Cell Mol Med (2008) 0.82

Cerebral correlates of psychotic syndromes in neurodegenerative diseases. J Cell Mol Med (2012) 0.81

Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy. Neurodegener Dis (2008) 0.77

Commentary on "Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples". Alzheimers Dement (2006) 0.77

Should the word 'dementia' be forgotten? J Cell Mol Med (2010) 0.75